U.S. pharma big copyright scrapped two experimental weight loss supplements past calendar year—a at the time-day by day pill, lotiglipron, on account of elevated liver enzymes plus a twice-day by day tablet, danuglipron, because of powerful Uncomfortable side effects—but CEO Albert Bourla has claimed the company is set to “play and earn” in